Serum laminin as a marker of diabetic retinopathy development: a 4-year follow-up study

• Published in: American journal of ophthalmology 2000-03, Vol.129 (3), p.347-352
• Main Authors: Masmiquel, Lluis, Segura, Rosa M, Mateo, Carlos, Calatayud, Marta, Martí, Ramón, Mesa, Jordi, Simó, Rafael
• Format: Article
• Language: English
• Subjects: Associated diseases and complications; Biological and medical sciences; Biomarkers - blood; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes. Impaired glucose tolerance; Diabetic Retinopathy - blood; Diabetic Retinopathy - etiology; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Female; Follow-Up Studies; Humans; Laminin - blood; Male; Medical sciences; Middle Aged; Peptide Fragments - blood; Prospective Studies; Radioimmunoassay; Risk Factors
• ISSN: 0002-9394; 1879-1891
• DOI: 10.1016/S0002-9394(99)00361-X

PURPOSE: The usefulness of laminin as a serum marker of diabetic retinopathy is a topic that generates conflicting views. The aim of the present study was to investigate the effect of diabetic retinopathy on serum laminin-P1, the larger pepsin resistant fragment of laminin, and to elucidate whether serum laminin-P1 could be an indicator of the risk for development of diabetic retinopathy. METHODS: In a prospective study, 97 consecutive diabetic patients (35 type 1 and 62 type 2) without diabetic retinopathy and a urinary albumin excretion rate lower than 20 μg per minute were enrolled in a 4-year follow-up study. Patients who developed microalbuminuria during the study were excluded in order to avoid the influence of diabetic nephropathy on serum laminin-P1. At the end of follow-up, data from ophthalmologic studies and serum laminin-P1 were evaluated in the 66 normoalbuminuric diabetic patients who completed the study. RESULTS: No statistical differences were observed in baseline laminin-P1 serum concentrations between patients who developed diabetic retinopathy (n = 15) and patients who remained without it during follow-up (n = 51). However, serum laminin-P1 levels obtained at the end of the study were significantly higher in patients who developed diabetic retinopathy (1.75 ± 0.33 U/ml versus 1.47 ± 0.27 U/ml; P = .002). Furthermore, statistical difference was observed when initial and final values of serum laminin-P1 were compared in patients who developed diabetic retinopathy (1.56 ± 0.27 U/ml versus 1.75 ± 0.33 U/ml; P = .001). Remarkably, an increase in serum laminin-P1 concentration was detected in all but two of the patients who developed diabetic retinopathy. The relative risk of development of diabetic retinopathy in patients who showed an increase in serum laminin-P1 during follow-up was 5.4 (95% confidence interval, 1.32 to 22.13). CONCLUSIONS: Serum laminin-P1 is a marker and a risk indicator of diabetic retinopathy but is not an early predictor of its development.